US FDA approves Novartis drug to treat kidney disease
The US Food and Drug Administration has approved the use of a Novartis drug to reduce excess protein in the urine of patients with a type of kidney disease. The drug Fabhalta is already approved to treat adults with paroxysmal nocturnal haemoglobinuria, a rare blood disorder.
ENTRADAS POPULARES
Poland prepares for peaking floods
septiembre 20, 2024
Italy evacuates thousands as Boris hits the north
septiembre 20, 2024
China and the US race to tame nuclear fusion for clean energy
septiembre 20, 2024
TRANSMISIÓN EN VIVO